- Home
- SPRY
as 12-17-2024 4:00pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 959.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.02 - $18.51 | Next Earning Date: | 11-13-2024 |
| Revenue: | $2,568,000 | Revenue Growth: | 8460.00% |
| Revenue Growth (this year): | 95526.66% | Revenue Growth (next year): | 275.98% |
Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dorsey Brian | SPRY | Chief Operating Officer | Dec 11 '24 | Sell | $12.36 | 40,000 | $493,858.50 | 6,024 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Dec 10 '24 | Sell | $13.16 | 100,000 | $1,316,420.00 | 1,246,494 | |
| Chakma Justin | SPRY | Chief Business Officer | Dec 10 '24 | Sell | $13.15 | 50,000 | $657,625.00 | 136,380 | |
| Chakma Justin | SPRY | Chief Business Officer | Dec 4 '24 | Sell | $14.11 | 144,640 | $2,041,200.04 | 136,380 | |
| Karas Eric | SPRY | Chief Commercial Officer | Dec 2 '24 | Sell | $14.06 | 10,000 | $140,423.37 | 5,693 | |
| Chakma Justin | SPRY | Chief Business Officer | Dec 2 '24 | Sell | $13.43 | 90,000 | $1,208,619.00 | 136,380 | |
| Shawver Laura | SPRY | Director | Dec 2 '24 | Sell | $13.73 | 200,000 | $2,688,750.95 | 210,346 | |
| Chakma Justin | SPRY | Chief Business Officer | Nov 25 '24 | Sell | $14.15 | 100,000 | $1,411,742.12 | 136,380 | |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Nov 19 '24 | Sell | $13.95 | 100,000 | $1,394,960.00 | 1,198,499 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Nov 19 '24 | Sell | $13.95 | 100,000 | $1,394,960.00 | 1,246,494 |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
ARS Pharmaceuticals Insider Sold Shares Worth $1,768,093, According to a Recent SEC Filing
MT Newswires
6 days ago
ARS Pharmaceuticals' Licensing Partners in China, Japan, Australia Seek Approval on Neffy Nasal Spray
GlobeNewswire
6 days ago
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
MT Newswires
9 days ago
ARS Pharmaceuticals Insider Sold Shares Worth $2,041,200, According to a Recent SEC Filing
MT Newswires
13 days ago
ARS Pharmaceuticals Insider Sold Shares Worth $2,688,751, According to a Recent SEC Filing
GlobeNewswire
14 days ago
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
Simply Wall St.
21 days ago
US Growth Stocks With High Insider Ownership For November 2024
Simply Wall St.
a month ago
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.